Ma Jiajin, Wu Yue, Wu Shaoxian, Fang Zhang, Chen Lujun, Jiang Jingting, Zheng Xiao
Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, China.
Cancer Sci. 2024 Dec;115(12):3838-3845. doi: 10.1111/cas.16359. Epub 2024 Oct 8.
CX3CR1 functions as the specific receptor for the chemokine CX3CL1, demonstrating expression across a broad spectrum of immune cells. This underscores its pivotal role in communication and response mechanisms within the immune system. Upon engagement with CX3CL1, CX3CR1 initiates a cascade of downstream signaling pathways that regulate various biological functions. In the context of tumor progression, the intricate and inhibitory nature of the tumor microenvironment presents a significant challenge to current clinical treatment techniques. This review aims to comprehensively explore the tumor-destructive potential shown by CX3CR1CD8 T cells. Simultaneously, it investigates the promising prospects of utilizing CX3CR1 in future tumor immunotherapies.
CX3CR1作为趋化因子CX3CL1的特异性受体,在广泛的免疫细胞中均有表达。这凸显了其在免疫系统内通讯和反应机制中的关键作用。与CX3CL1结合后,CX3CR1会启动一系列下游信号通路,从而调节各种生物学功能。在肿瘤进展的背景下,肿瘤微环境的复杂性和抑制性对当前的临床治疗技术构成了重大挑战。本综述旨在全面探讨CX3CR1⁺ CD8⁺ T细胞所展现出的肿瘤破坏潜力。同时,研究在未来肿瘤免疫治疗中利用CX3CR1的前景。